Sage Therapeutics Inc. (NASDAQ:SAGE) shares saw unusually-high trading volume on Thursday . Approximately 1,584,366 shares were traded during trading, an increase of 10% from the previous session’s volume of 1,434,334 shares.The stock last traded at $40.68 and had previously closed at $42.43.

SAGE has been the subject of a number of recent analyst reports. Leerink Swann reissued a “buy” rating on shares of Sage Therapeutics in a research report on Monday, May 16th. Canaccord Genuity reissued a “buy” rating on shares of Sage Therapeutics in a research report on Wednesday, June 8th. Cowen and Company reissued a “buy” rating on shares of Sage Therapeutics in a research report on Wednesday, June 8th. Zacks Investment Research downgraded shares of Sage Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Goldman Sachs Group Inc. reissued a “buy” rating and set a $63.00 price target on shares of Sage Therapeutics in a research report on Friday, April 1st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $66.18.

The company’s market cap is $1.35 billion. The stock’s 50 day moving average price is $32.43 and its 200-day moving average price is $34.97.

Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.97) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.98) by $0.01. On average, equities analysts anticipate that Sage Therapeutics Inc. will post ($4.34) EPS for the current fiscal year.

In related news, insider Albert Robichaud sold 22,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 12th. The stock was sold at an average price of $40.00, for a total value of $880,000.00. Following the completion of the sale, the insider now directly owns 140,222 shares in the company, valued at approximately $5,608,880. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Kimi Iguchi sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 12th. The stock was sold at an average price of $49.55, for a total value of $247,750.00. Following the completion of the sale, the chief financial officer now owns 83,739 shares of the company’s stock, valued at $4,149,267.45. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have modified their holdings of the company. Nationwide Fund Advisors increased its position in shares of Sage Therapeutics by 9.4% in the fourth quarter. Nationwide Fund Advisors now owns 21,143 shares of the biopharmaceutical company’s stock valued at $1,233,000 after buying an additional 1,816 shares in the last quarter. California State Teachers Retirement System increased its position in shares of Sage Therapeutics by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 25,578 shares of the biopharmaceutical company’s stock valued at $1,491,000 after buying an additional 400 shares in the last quarter. ProShare Advisors LLC increased its position in shares of Sage Therapeutics by 8.2% in the fourth quarter. ProShare Advisors LLC now owns 25,219 shares of the biopharmaceutical company’s stock valued at $1,470,000 after buying an additional 1,919 shares in the last quarter. GAM Holding AG increased its position in shares of Sage Therapeutics by 74.1% in the fourth quarter. GAM Holding AG now owns 79,400 shares of the biopharmaceutical company’s stock valued at $4,629,000 after buying an additional 33,800 shares in the last quarter. Finally, Wells Fargo & Company MN increased its position in shares of Sage Therapeutics by 62.6% in the fourth quarter. Wells Fargo & Company MN now owns 24,804 shares of the biopharmaceutical company’s stock valued at $1,446,000 after buying an additional 9,548 shares in the last quarter.

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening, rare central nervous system (CNS) disorders. The Company’s lead product candidate in its status epilepticus (SE) program is SAGE-547. SAGE-689 and SAGE-217 are two additional product candidates in its pipeline.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.